Altimmune Reports $0 Revenue, Widened $22.6M Net Loss in Q1
ALT sits 17% above its 52-week low of $2.56.
Summary
Altimmune, Inc. reported its first-quarter 2026 financial results, showing no revenue and a net loss of $22.6 million, which widened by 15% year-over-year. Diluted loss per share improved to $(0.18) from $(0.26) in the prior year. This detailed financial update from the 10-Q follows an earlier 8-K announcement of Q1 results, providing specific figures. For a pre-revenue biotech company, these figures are crucial for assessing cash burn and financial runway, especially as the company advances its costly pivotal Phase III MASH trial. Investors will closely watch the company's cash position relative to its operational expenses.
At the time of this announcement, ALT was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $587M. The 52-week trading range was $2.56 to $7.73. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.